| 1 |
Melvin AJ, Yee KL, Gray KP, Yedla M, Wan H, Tobin NH, Teppler H, Campbell H, McCarthy K, Scheckter R, Aurpibul L, Ounchanum P, Rungmaitree S, Cassim H, McFarland E, Flynn P, Cooper E, Krotje C, Townley E, Moye J, Best BM; IMPAACT 2014 study team. Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014. J Acquir Immune Defic Syndr 2023;92:153-61. [PMID: 36215957 DOI: 10.1097/QAI.0000000000003116] [Reference Citation Analysis]
|
| 2 |
Iannone V, Farinacci D, D'Angelillo A, Dusina A, Lamanna F, Passerotto R, Baldin G, Visconti E, Tamburrini E, Borghetti A, Di Giambenedetto S, Ciccullo A. Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life. AIDS Res Hum Retroviruses 2022;38:878-80. [PMID: 36166220 DOI: 10.1089/AID.2022.0050] [Reference Citation Analysis]
|
| 3 |
Mazzitelli M, Antoni MD, Castelli F, Ripamonti D, Zuglian G, Lapadula G, Fabbiani M, Ferraresi A, Putaggio C, Cattelan AM, Quiros-Roldan E. Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study. Medicine (Baltimore) 2022;101:e29855. [PMID: 35905209 DOI: 10.1097/MD.0000000000029855] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Taramasso L, Lo Caputo S, Magnasco L, Briano F, Poliseno M, Bruno SR, Ferrara S, Pincino R, Sarteschi G, Beltramini S, Sasso E, Mora S, Giacomini M, Bassetti M, Di Biagio A. Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV. AIDS Res Hum Retroviruses 2022;38:472-9. [PMID: 35172617 DOI: 10.1089/AID.2021.0161] [Reference Citation Analysis]
|
| 5 |
Sapuła M, Suchacz M, Załęski A, Wiercińska-Drapało A. Impact of Combined Antiretroviral Therapy on Metabolic Syndrome Components in Adult People Living with HIV: A Literature Review. Viruses 2022;14:122. [PMID: 35062326 DOI: 10.3390/v14010122] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 6 |
Stockdale AJ, Khoo S. Doravirine: its role in HIV treatment. Curr Opin HIV AIDS 2022;17:4-14. [PMID: 34740228 DOI: 10.1097/COH.0000000000000709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 7 |
Pond RA, Collins LF, Lahiri CD. Sex Differences in Non-AIDS Comorbidities Among People With Human Immunodeficiency Virus. Open Forum Infect Dis 2021;8:ofab558. [PMID: 34888399 DOI: 10.1093/ofid/ofab558] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 8 |
Emond B, Rossi C, Côté-Sergent A, Bookhart B, Anderson D, Lefebvre P, Lafeuille MH, Donga P. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States. Curr Med Res Opin 2021;:1-26. [PMID: 34812097 DOI: 10.1080/03007995.2021.2007006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 9 |
Farinacci D, Ciccullo A, Lombardi F, Moschese D, D’angelillo A, Iannone V, Lamanna F, Passerotto RA, Giambenedetto SD. Evaluation of doravirine-based regimen population target in a large Italian clinical center. Antiviral Therapy 2021;26:79-83. [DOI: 10.1177/13596535211056556] [Reference Citation Analysis]
|
| 10 |
Benedicto AM, Fuster-Martínez I, Tosca J, Esplugues JV, Blas-García A, Apostolova N. NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved. Cells 2021;10:1687. [PMID: 34359857 DOI: 10.3390/cells10071687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
